Day 2 :
- Organ Specific Cancer | Oncology Radialogy, Nanotechnology | Neurological Cancers & Brain Tumors | Gynaecological Cancers | Cancer Early Detection, Diagnosis and Prognosis
Session Introduction
Michaela Bercovitch
Saakler School of Medicine' Tel Aviv University, Israel.
Title: WHERE WILL THE FUTURE OF THE HOSPICE LEAD US?
Biography:
Dr Michaela Bercovich is the director of the Oncological Hospice in Sheba hospital, Tel HaShomer, Israel and a lecturer at Tel Aviv University Sackler School of Medicine. Dr. Bercovitch was born in Romania, Bucharest, where she graduated from medical school as MD in Pediatrics. In 1987 she emigrated to Israel and after two years training in Internal Medicine and Geriatrics she continued her medical practice in the Oncological Hospice. In 1998 she initiated a 2 year comprehensive postgraduate course of Palliative Medicine for doctors. She is involved in the education of medical students, nurses and doctors across Israel. Her research fields include pain control, impact of high dose opioids on patients’ survival, development of clinical auditing tools and a hospice oriented clinical database. She is the author of the chapter discussing treatment of pain with TENS (Oxford Textbook of Palliative Medicine), and other chapters addressing euthanasia, non-pharmacological treatments for chronic pain, the role of the physician near death, and the effect of patient-setting on the work of the team. Dr Bercovitch was a member of the Directory of European Association for Palliative Care (2007-2016); Served as the Chairperson of Israeli Palliative Medicine Society (2002-2016) focusing on the recognition of Palliative Medicine as a sub-specialty and its inclusion as a government funded treatment. Along the years she has actively participated in the conception and promulgation of the first Israeli law regarding the dying patient.
Abstract:
"We are here not only to help you to die but also to help you to live until you die." – Cecily Saunders. The unavoidable and inevitable tragedy of death is based on our lack of acceptance of the process of dying. There is a certain point where medical intervention no longer protects the living but hinders us and denies us the integrity of a quality of living until the end. At the hospice it is our philosophy to accept the imminent loss of life while at the same time celebrating every remaining moment with outmost comfort comfort and peace of mind.
With the plethora of new oncologic treatments, and the ever growing ease of their administration, it is becoming a struggle to find and draw the line beyond which "fighting the disease" is no longer a valid option. There is a steep cost for the patient and even more so for his family when false hope is nourished and quality of life is negatively attended. The hospice is an essential incubator that provides warmth, comfort and love not only for our patients, but for their loved ones. It is a time of contemplation and acceptance, where the patient regains their identity while simultaneously reaching closure. We struggle daily to protect this inherent human right, and it is essential to keep the hospice an independent environment where quality excels quantity. We will support our affirmations with some clinical testimonies and a short film.
Jana Slobodnikova
Alexander Dubcek University of Trencin, Slovakia
Title: ANALYSES OF ROUTINELY TESTED TUMOR MARKERS, QUALITY CONTROL OF THE LABORATORY
Biography:
Jana Slobodnikova. M.D., end study on Charles University in Prague., gradued - CSc / PhD / completed at the age 38 years from Institus of Experimental Oncology Slovac Scientic Academy. Ass. Prof. in 43 years from Trnaviensis University, Prof. emeritus at age 45 years from St. Elizabeth High Scool. I have lectured at several universities - Prague, Tren?ín, Trnava and Bratislava. I am the author of teaching script, university textbooks, I lead workshops, I organize international congresses and worksops Her has published more than 90 scientific papers, from then 25 papers in renomed journals and has been serving as an 5 editorial board member of repute. Her has published 3 monography, Her founded the Section of Breast Imaging in 1996, from 1996 her is president The Section of Breast Imaging of Slovak radiologic Society and vice president The Slovak Society of Ultrasound in Medicine. Membership in organizations : ECR, EUSOBI, EFSUMB , SSUM ( Slovak Society of Ultrasound in Medicine ) and SRS ( Slovak Radiology Society).
Abstract:
Tumor markers are an important tools in laboratory diagnostics of cancer diseases, which allows us continual supervision of patients´ stage and its time-dynamics. Thanks to this laboratory parameters, recidiving diseases can be treated significantly earlier. In our study we evaluated routinely tested tumor markers CA125, Ca199, CEA, PSA, AFP, HCG and Ca153 with emphasis on their diagnostic value in clinical practice.
Aim
The goal of our preliminar study was to verify the informational quality of tested parameters in terms of precision, accuracy and reliability of results with the aim of the external quality control (EQC).
Material and methods
All listed tumor markers were determined by laboratory methods based on the principle of electrochemiluminescence. The anonymous material for the analysis was provided by a supplier of the external quality control in the form of sample pairs with an undisclosed concentration of the analyte.
After processing there were obtained concentrations of particular analytes and they were sent back to the supplier of external quality control for evaluation. Acceptable outcomes were cut-off values which didn´t exceed 20% of the CV of the group, to which laboratory methodologically belonged.
Abdalla Abotaleb
World Health Organisation, Egypt
Title: Impact of innovative treatments on economic burden of hepatocellular carcinoma At low middle income countries
Biography:
Abdalla Abo Taleb, MD is a World Health Organization expert. He is also a consultant on health economics at the Egyptian Ministry of Health, as well as a member of the Egyptian health care reforming committee Ispor (member, judge and reviewer).
Abstract:
At low middle income countries like Egypt with prevalence of (HCV) which represent From 5 to 7% of total population.
Hepatocellular carcinoma is one of major complications of HCV infection
At Africa for example Egypt is accounting for approximately half of the data related to HCC .Over the last two decades, a substantial increase (from 4.0% to 7.2%) in the proportion of chronic liver disease Egyptian patients with HCC was observed. This percentage raise some questions like
- How government afford innovative products for high number of patients?
- Are these innovative products worthy for reimbursement?
- What are the impact on budget?
The main objective behind conducting this study was to conduct an economic evaluation of Sorafenib for the treatment of hepatocellular carcinoma in the Egyptian patients, compared to standard of care perspective of the National Fund over a time horizon of 4 years.
To maximize health gain for the patients while ensuring the most efficient use of the finite resources available to the Egyptian Ministry of Health.
Methods
A cost-effectiveness analysis from the payer perspective using Markov chain simulation model which is hypothetical cohort model to conforms to real practice of management of advanced HCC in Egypt.
Four years' time horizon was selected to reflect the consequences of a decision. transition probabilities from "first line until progression" state to "best supportive care" and "death" were derived from previously published studies; the SHARP study.
Biography:
Graduated from Toho Academy of Music in Tokyo, as a pianist and composer, invited by the Boston Symphony, she came to the USA in 1961 as one of the first Japanese women. She then received Master of Art from New York University and finished her Ph.D. credits in Philosophy in 1965. In 1967, Tatsumura then turned to an independent career and became the top International Classical and Cultural Impresario/producer. Until 1992, she produced an average of 2,000 cultural events each year, traveling to more than 140 countries. She was presented with numerous honors for her work from different countries, many for humanitarian causes. She is also well known as a philanthropist.
She studied Oriental Traditional Medicine of Japan, Korea, Taiwan and China. In 2000 she received her PHD and OMD from the International Academy of Education in Tokyo. She established the Oki-Do Holistic Health Center in 1994 in NY and in 2001 the GAIA Holistic Center (501C3 nonprofit organization) at the wake of 9/11 tragedy, for body mind and spirit, aiming for the noninvasive natural healing methods based on the wisdom of the East. She invented special holistic healing method called ONNETSU THERMOTHERAPY using Heat and 2 vibrations of Sun Far Infra-red (8-10μ) and Terahertz from deep earth planet minerals. The therapy has been widely hailed in hospitals and clinics especially in South Americas. Her invention is patent pending worldwide. Dr. Kazuko Tatsumura has written numerous articles and several books: e.g. “Overcoming Cancer and Other Diseases in a Holistic Way”, “Your Immune Revolution & Healing Your Healing Power” (with Toru Abo, M.D.). Dr. Kazuko has been invited as a speaker at various World Congresses & International Conferences on Alternative & Holistic Health. She teaches and lectures to MDs and practitioners all over the world
Abstract:
Dr. Juan Ariel Jara Guerrero
Universidad Complutense de Madrid, Spain
Title: Iron in the Oncogenesis: Its role in Cancer Progression and de Novo Cancer Initiation in Humans How the Free Iron worse the Insulin Resistance
Biography:
Abstract:
Dr. Segundo Mesa Castillo
Psychiatric Hospital of Havana, Cuba
Title: Direct evidence of viral infection and mitochondrial alterations in the brain of fetuses at high risk for schizophrenia
Biography:
Segundo Mesa Castillo. As Specialist in Neurology, he worked for 10 years in the Institute of Neurology of Havana, Cuba. He has worked in Electron Microscopic Studies on Schizophrenia for 32 years. He was awarded with the International Price of the Stanley Foundation Award Program and for the Professional Committee to work as a fellowship position in the Laboratory of the Central Nervous System Studies, National Institute of Neurological Diseases and Stroke under Dr. Joseph Gibbs for a period of 6 months, National Institute of Health, Bethesda, Maryland, Washington D.C. USA, June 5, 1990.
Abstract:
There is increasing evidences that favor the prenatal beginning of schizophrenia. These evidences point toward intra-uterine environmental factors that act specifically during the second pregnancy trimester producing a direct damage of the brain of the fetus. The current available technology doesn't allow observing what is happening at cellular level since the human brain is not exposed to a direct analysis in that stage of the life in subjects at high risk of developing schizophrenia. Methods. In 1977 we began a direct electron microscopic research of the brain of fetuses at high risk from schizophrenic mothers in order to finding differences at cellular level in relation to controls. Results. In these studies we have observed within the nuclei of neurons the presence of complete and incomplete viral particles that reacted in positive form with antibodies to herpes simplex hominis type I [HSV1] virus, and mitochondria alterations. Conclusion. The importance of these findings can have practical applications in the prevention of the illness keeping in mind its direct relation to the aetiology and physiopathology of schizophrenia. A study of amniotic fluid cells in women at risk of having a schizophrenic offspring is considered. Of being observed the same alterations that those observed previously in the cells of the brain of the studied foetuses, it would intend to these women in risk of having a schizophrenia descendant, previous information of the results, the voluntary medical interruption of the pregnancy or an early anti HSV1 viral treatment as preventive measure of the later development of the illness
Dr.Vikas Leelavati Balasaheb Jadhav
Dr.D.Y.Patil Medical College, Hospital & Research Centre, India
Title: Sonography of the Neoplastic Diseases in the Gastro-Intestinal Tract
Biography:
Dr.Vikas Leelavati BalaSaheb Jadhav has completed PostGraduation in Radiology in 1994. He has a 25 Years of experience in the field of Gastro-Intestinal Tract Ultrasound & Diagnostic as well Therapeutic Interventional Sonography. He is the Pioneer of Gastro-Intestinal Tract Sonography, especially Gastro-Duodenal Sonography. He has delivered many Guest Lectures in Indian as well International Conferences in nearly 27 countries as an Invited Guest Faculty, since March 2000. He is a Consultant Radiologist & the Specialist in Conventional as well Unconventional Gastro-Intestinal Tract Ultrasound & Diagnostic as well Therapeutic Interventional Sonologist in Pune, India.
Abstract:
Sonography of the Gastro-Intestinal Tract can reveal intra-mural tumours, Intra-mural haematoma, Lesions of Ampulla of Vater like benign & infiltrating mass lesions. Neoplastic lesion is usually a segment involvement, & shows irregularly thickened, hypoechoic & aperistaltic wall with loss of normal layering pattern. It is usually a solitary stricture & has eccentric irregular luminal narrowing. It shows loss of normal Gut Signature. Enlargement of the involved segment seen. Shouldering effect at the ends of stricture is most common feature. Enlarged lymphnodes around may be seen. Primary arising from wall itself & secondary are invasion from peri-Ampullary malignancy or distant metastasis. All these cases are compared & proved with gold standards like surgery & endoscopy.
Some extra efforts taken during all routine or emergent ultrasonography examinations can be an effective non-invasive method to diagnose primarily hitherto unsuspected benign & malignant Gastro-Intestinal Tract lesions, so should be the investigation of choice.